Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Prothena Corp (PRTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 461,180
  • Shares Outstanding, K 39,860
  • Annual Sales, $ 27,520 K
  • Annual Income, $ -153,240 K
  • 36-Month Beta 2.57
  • Price/Sales 16.46
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.96
  • Number of Estimates 3
  • High Estimate -0.87
  • Low Estimate -1.08
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +22.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.84 +8.67%
on 11/14/18
12.58 -6.36%
on 11/27/18
-0.63 (-5.08%)
since 11/09/18
3-Month
10.84 +8.67%
on 11/14/18
14.67 -19.70%
on 09/24/18
-2.27 (-16.16%)
since 09/11/18
52-Week
10.43 +12.94%
on 04/25/18
46.14 -74.47%
on 01/29/18
-28.26 (-70.58%)
since 12/11/17

Most Recent Stories

More News
Implied Volatility Surging for Prothena (PRTA) Stock Options

Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.

PRTA : 11.86 (+2.51%)
Prothena (PRTA) Down 12.3% Since Last Earnings Report: Can It Rebound?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PRTA : 11.86 (+2.51%)
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3

Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.

CELG : 69.79 (+1.62%)
PRTA : 11.86 (+2.51%)
GILD : 67.96 (+0.70%)
RHHBY : 31.5601 (+0.10%)
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 33.33% and -2.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

PRTA : 11.86 (+2.51%)
Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update

- Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted cash position of $455.6 million...

PRTA : 11.86 (+2.51%)
Prothena to Report Third Quarter 2018 Financial Results on November 6

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of...

PRTA : 11.86 (+2.51%)
Prothena to Report Third Quarter 2018 Financial Results on November 6

DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine...

PRTA : 11.86 (+2.51%)
Will Prothena (PRTA) Report Negative Earnings Next Week? What You Should Know

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRTA : 11.86 (+2.51%)
Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View

Celgene (CELG) third-quarter revenues gain on strong sales of Otezla and Revlimid.

CELG : 69.79 (+1.62%)
BLUE : 104.60 (+2.40%)
XLRN : 47.87 (-0.48%)
PRTA : 11.86 (+2.51%)
Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018 - Featuring Eustralis Pharmaceuticals, Prothena Corporation and Tetra Discovery Partners - ResearchAndMarkets.com

The "Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

PRTA : 11.86 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PRTA with:

Business Summary

Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and...

See More

Key Turning Points

2nd Resistance Point 12.09
1st Resistance Point 11.83
Last Price 11.86
1st Support Level 11.19
2nd Support Level 10.81

See More

52-Week High 46.14
Fibonacci 61.8% 32.50
Fibonacci 50% 28.28
Fibonacci 38.2% 24.07
Last Price 11.86
52-Week Low 10.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar